Citadel Advisors’s Healthcare Services Acquisition Corporation Class A Common Stock HCAR Stock Holding History

Citadel Advisors’s Portfolio HCAR Stock Details HCAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300,236	Closed	-$2.98M	–	15824
2022 Q3	$2.98M	Buy	300,236 +3,447	+1%	+$34.1K	﹤0.01%	4821
2022 Q2	$2.92M	Sell	296,789 -601,111	-67%	-$5.91M	﹤0.01%	4799
2022 Q1	$8.8M	Sell	897,900 -1,180	-0.1%	-$11.5K	﹤0.01%	3161
2021 Q4	$8.78M	Sell	899,080 -10,434	-1%	-$102K	﹤0.01%	3287
2021 Q3	$8.85M	Buy	909,514 +299,303	+49%	+$2.9M	﹤0.01%	3279
2021 Q2	$5.91M	Buy	610,211 +7,558	+1%	+$73.4K	﹤0.01%	4088
2021 Q1	$5.83M	Buy	+602,653	New	+$6.04M	﹤0.01%	3928

Citadel Advisors's HCAR Position: Q4 2022 in Review

Citadel Advisors sold out of Healthcare Services Acquisition Corporation Class A Common Stock (HCAR) in Q4 2022, closing a stake of 300,236 shares — an estimated $2.98M sold.

Citadel Advisors first reported a position in HCAR in Q1 2021 and held it in 7 quarters. The position peaked at $8.85M in Q3 2021. 0 funds tracked by Wall St. Rank hold HCAR as of Q4 2022.

Citadel Advisors reported no remaining Healthcare Services Acquisition Corporation Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 300,236 Healthcare Services Acquisition Corporation Class A Common Stock shares in Q4 2022, an estimated $2.98M.
Citadel Advisors first reported a position in Healthcare Services Acquisition Corporation Class A Common Stock in Q1 2021 and held it in 7 quarters.
Citadel Advisors's Healthcare Services Acquisition Corporation Class A Common Stock position peaked at $8.85M in Q3 2021.
0 funds tracked by Wall St. Rank held Healthcare Services Acquisition Corporation Class A Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.